The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

Giuseppe Cicero, Antonio Russo, Rosalba Rossello, Barbara Adamo, Tindara Franchina, Giuseppa Ferraro, Giuseppina Rosaria Rita Ricciardi, Mariangela Zanghì, Nicola Caristi, Vincenzo Adamo, Sergio Rizzo

Risultato della ricerca: Article

24 Citazioni (Scopus)

Abstract

AbstractBackground: Breast cancer in the elderly is associated withhigh recurrence and death rates, due mostly to undertreatment.Human epidermal growth factor receptor type 2(HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderlypatients because of its cardiotoxicity. Patients and Methods:Medical records of consecutive HER2-positive breastcancer patients aged ≥ 70 years old treated between 2005and 2010 in the participating centers were retrospectivelyreviewed. All patients underwent multidimensional geriatricassessment (MGA). Results: Among 59 patients identified,51 patients were evaluable (median age 76 years). The rateof any adverse event was 20% (10/51). The most relevant cardiacadverse event consisted of symptomatic congestiveheart failure (CHF; n = 1, 2%) followed by asymptomatic decreasesof left ventricular ejection fraction (LVEF; n = 6, 12%).Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6%). Hypertension,obesity, prior anthracyclines exposure and concurrentchemotherapy were associated with a higher incidence oftoxic events. Previous radiotherapy, concurrent endocrinetherapy and different trastuzumab-based regimens did notseem to influence toxicity. Conclusions: Our data suggestthat trastuzumab has a good safety profile in nonfrail womenaged 70 years and older. These favorable findings may berelated to a limited number of anthracycline pretreatments,patient selection and a close cardiologic monitoring.
Lingua originaleEnglish
pagine (da-a)16-21
Numero di pagine6
RivistaOncology
Volume86
Stato di pubblicazionePublished - 2013

Fingerprint

Breast Neoplasms
Population
Anthracyclines
Stroke Volume
Patient Selection
Medical Records
Trastuzumab
Hypersensitivity
Radiotherapy
Obesity
Hypertension
Safety
Recurrence
Drug Therapy
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Cicero, G., Russo, A., Rossello, R., Adamo, B., Franchina, T., Ferraro, G., ... Rizzo, S. (2013). The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population. Oncology, 86, 16-21.

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population. / Cicero, Giuseppe; Russo, Antonio; Rossello, Rosalba; Adamo, Barbara; Franchina, Tindara; Ferraro, Giuseppa; Ricciardi, Giuseppina Rosaria Rita; Zanghì, Mariangela; Caristi, Nicola; Adamo, Vincenzo; Rizzo, Sergio.

In: Oncology, Vol. 86, 2013, pag. 16-21.

Risultato della ricerca: Article

Cicero, G, Russo, A, Rossello, R, Adamo, B, Franchina, T, Ferraro, G, Ricciardi, GRR, Zanghì, M, Caristi, N, Adamo, V & Rizzo, S 2013, 'The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population', Oncology, vol. 86, pagg. 16-21.
Cicero, Giuseppe ; Russo, Antonio ; Rossello, Rosalba ; Adamo, Barbara ; Franchina, Tindara ; Ferraro, Giuseppa ; Ricciardi, Giuseppina Rosaria Rita ; Zanghì, Mariangela ; Caristi, Nicola ; Adamo, Vincenzo ; Rizzo, Sergio. / The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population. In: Oncology. 2013 ; Vol. 86. pagg. 16-21.
@article{7748eba964bf4e6a887c8b08608fe6f7,
title = "The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population",
abstract = "AbstractBackground: Breast cancer in the elderly is associated withhigh recurrence and death rates, due mostly to undertreatment.Human epidermal growth factor receptor type 2(HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderlypatients because of its cardiotoxicity. Patients and Methods:Medical records of consecutive HER2-positive breastcancer patients aged ≥ 70 years old treated between 2005and 2010 in the participating centers were retrospectivelyreviewed. All patients underwent multidimensional geriatricassessment (MGA). Results: Among 59 patients identified,51 patients were evaluable (median age 76 years). The rateof any adverse event was 20{\%} (10/51). The most relevant cardiacadverse event consisted of symptomatic congestiveheart failure (CHF; n = 1, 2{\%}) followed by asymptomatic decreasesof left ventricular ejection fraction (LVEF; n = 6, 12{\%}).Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6{\%}). Hypertension,obesity, prior anthracyclines exposure and concurrentchemotherapy were associated with a higher incidence oftoxic events. Previous radiotherapy, concurrent endocrinetherapy and different trastuzumab-based regimens did notseem to influence toxicity. Conclusions: Our data suggestthat trastuzumab has a good safety profile in nonfrail womenaged 70 years and older. These favorable findings may berelated to a limited number of anthracycline pretreatments,patient selection and a close cardiologic monitoring.",
author = "Giuseppe Cicero and Antonio Russo and Rosalba Rossello and Barbara Adamo and Tindara Franchina and Giuseppa Ferraro and Ricciardi, {Giuseppina Rosaria Rita} and Mariangela Zangh{\`i} and Nicola Caristi and Vincenzo Adamo and Sergio Rizzo",
year = "2013",
language = "English",
volume = "86",
pages = "16--21",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

AU - Cicero, Giuseppe

AU - Russo, Antonio

AU - Rossello, Rosalba

AU - Adamo, Barbara

AU - Franchina, Tindara

AU - Ferraro, Giuseppa

AU - Ricciardi, Giuseppina Rosaria Rita

AU - Zanghì, Mariangela

AU - Caristi, Nicola

AU - Adamo, Vincenzo

AU - Rizzo, Sergio

PY - 2013

Y1 - 2013

N2 - AbstractBackground: Breast cancer in the elderly is associated withhigh recurrence and death rates, due mostly to undertreatment.Human epidermal growth factor receptor type 2(HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderlypatients because of its cardiotoxicity. Patients and Methods:Medical records of consecutive HER2-positive breastcancer patients aged ≥ 70 years old treated between 2005and 2010 in the participating centers were retrospectivelyreviewed. All patients underwent multidimensional geriatricassessment (MGA). Results: Among 59 patients identified,51 patients were evaluable (median age 76 years). The rateof any adverse event was 20% (10/51). The most relevant cardiacadverse event consisted of symptomatic congestiveheart failure (CHF; n = 1, 2%) followed by asymptomatic decreasesof left ventricular ejection fraction (LVEF; n = 6, 12%).Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6%). Hypertension,obesity, prior anthracyclines exposure and concurrentchemotherapy were associated with a higher incidence oftoxic events. Previous radiotherapy, concurrent endocrinetherapy and different trastuzumab-based regimens did notseem to influence toxicity. Conclusions: Our data suggestthat trastuzumab has a good safety profile in nonfrail womenaged 70 years and older. These favorable findings may berelated to a limited number of anthracycline pretreatments,patient selection and a close cardiologic monitoring.

AB - AbstractBackground: Breast cancer in the elderly is associated withhigh recurrence and death rates, due mostly to undertreatment.Human epidermal growth factor receptor type 2(HER2) overexpression is infrequent in older patients. Trastuzumab-based chemotherapy is often withheld from elderlypatients because of its cardiotoxicity. Patients and Methods:Medical records of consecutive HER2-positive breastcancer patients aged ≥ 70 years old treated between 2005and 2010 in the participating centers were retrospectivelyreviewed. All patients underwent multidimensional geriatricassessment (MGA). Results: Among 59 patients identified,51 patients were evaluable (median age 76 years). The rateof any adverse event was 20% (10/51). The most relevant cardiacadverse event consisted of symptomatic congestiveheart failure (CHF; n = 1, 2%) followed by asymptomatic decreasesof left ventricular ejection fraction (LVEF; n = 6, 12%).Other toxicities included moderate hypersensitivity reactions during trastuzumab infusions (n = 3, 6%). Hypertension,obesity, prior anthracyclines exposure and concurrentchemotherapy were associated with a higher incidence oftoxic events. Previous radiotherapy, concurrent endocrinetherapy and different trastuzumab-based regimens did notseem to influence toxicity. Conclusions: Our data suggestthat trastuzumab has a good safety profile in nonfrail womenaged 70 years and older. These favorable findings may berelated to a limited number of anthracycline pretreatments,patient selection and a close cardiologic monitoring.

UR - http://hdl.handle.net/10447/99179

M3 - Article

VL - 86

SP - 16

EP - 21

JO - Oncology

JF - Oncology

SN - 0030-2414

ER -